KRAS and cancer: Double-mutant mice with deletion of tumor suppressor PTEN and overexpression of oncogenic KRAS (PR(cre/+)Pten(f/f)Kras(G12D) had severe tumor burden and more invasive cancers than littermates with single mutations.